Biotech Industry · global
Pfizer pays $330 million to license Starna’s in vivo CAR-T programs targeting autoimmune diseases
Three programs that have yet to enter human trials mark Pfizer’s bet on therapies that modify immune cells directly inside the body. The deal’s potential value reaches $2.63 billion, but whether the delivery technology can translate into safe, effective treatments still requires clinical validation.
If immune cells can be modified directly inside a patient’s body, CAR-T therapy could potentially eliminate the complex process of collecting cells, sending them for processing outside the body, and reinfusing them. On November 18, Pfizer announced an exclusive licensing agreement with Starna Therapeutics for three in vivo CAR-T programs targeting autoimmune diseases, committing funding and manufacturing resources to this treatment approach, which remains in early development.
According to Pfizer’s announcement, Starna will receive a $330 million upfront payment, plus up to $2.3 billion in payments contingent on development and commercial milestones, as well as royalties on net sales of any products approved in the future. The $2.63 billion figure is therefore the maximum combined value of the upfront payment and potential milestone payments, rather than an amount certain to be paid, and excludes royalties.
The license covers development, manufacturing, and commercialization rights outside Greater China. Pfizer will lead clinical development in that territory and plans to manufacture finished drug products for initial clinical trials at U.S. facilities. The agreement also gives Pfizer an option to expand the licensed territory to include Greater China in the future.
The concept behind in vivo CAR-T is to deliver the instructions needed to modify T cells directly into the body, enabling the cells to recognize specific targets. In the announcement, Starna identified its targeted lipid nanoparticle (LNP) delivery platform and RNA technology as the foundation for advancing these therapies. Compared with processes that require cells to be handled outside the body, this approach could change manufacturing and administration arrangements, but whether it can reduce the treatment burden still requires supporting data.
The collaboration extends beyond these three candidate programs. Pfizer obtained rights to use Starna’s in vivo CAR-T technology in inflammation, immunology, and oncology, along with an option to exclusively license another candidate compound arising from a research collaboration. The deal therefore covers both existing programs and subsequent research and development opportunities, but this does not establish that all future candidate therapies will enter clinical trials.
All three programs are currently at the stage before applications to begin human trials. The announcement did not disclose the molecular targets, specific autoimmune diseases, preclinical efficacy data, or planned trial timelines for the individual programs, nor did it report patient treatment outcomes. It is therefore not yet possible to determine which patients they may be suitable for or what advantages they may offer over existing therapies.
The next key questions are whether the delivery system can accurately deliver instructions to the intended cells and whether the modified immune response can provide sufficient efficacy with acceptable safety. This deal establishes funding, rights, and the division of development responsibilities. Bringing the concept of producing therapeutic cells directly inside the body to patients will still require overcoming hurdles in manufacturing quality, clinical trials, and regulatory review.